tipifarnib has been researched along with Chagas Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buckner, FS; Gelb, MH; Hucke, O; Verlinde, CL | 1 |
| Buckner, FS; Gelb, MH; Karimi, M; Kraus, JM; Lepesheva, GI; Verlinde, CL | 1 |
| Arif, J; Buckner, FS; Chennamaneni, NK; Gelb, MH | 1 |
| Arif, J; Buckner, FS; Chennamaneni, NK; Gelb, MH; Karimi, M; Kraus, JM; McGuffin, SA; Tatipaka, HB; Verlinde, CL | 1 |
| Bahia, MT; Buckner, FS; Charman, SA; Chatelain, E; Chennamaneni, NK; Gelb, MH; Hulverson, MA; Laydbak, JU; Lepesheva, GI; Scandale, I; Shackleford, DM; Suryadevara, PK; Verlinde, CL; White, KL | 1 |
5 other study(ies) available for tipifarnib and Chagas Disease
| Article | Year |
|---|---|
The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease.
Topics: Alkyl and Aryl Transferases; Animals; Binding Sites; Chagas Disease; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Lanosterol; Models, Molecular; Oxidoreductases; Protein Binding; Quinolones; Sterol 14-Demethylase; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma cruzi | 2005 |
Rational modification of a candidate cancer drug for use against Chagas disease.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Chagas Disease; Humans; Mice; Mice, Inbred BALB C; Models, Molecular; Quinolones; Rats; Trypanocidal Agents | 2009 |
Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents.
Topics: Animals; Antineoplastic Agents; Chagas Disease; Drug Evaluation, Preclinical; Mice; Molecular Conformation; Parasitic Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma cruzi | 2009 |
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.
Topics: 3T3 Cells; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Chagas Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Isoenzymes; Mice; Models, Molecular; Protein Binding; Quinolones; Rats; Sterol 14-Demethylase; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma cruzi | 2010 |
Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib.
Topics: 14-alpha Demethylase Inhibitors; Administration, Oral; Alkyl and Aryl Transferases; Animals; Chagas Disease; Crystallography, X-Ray; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Female; Humans; Mice; Models, Molecular; Nitroimidazoles; Quinolones; Structure-Activity Relationship; Triazoles; Trypanocidal Agents; Trypanosoma cruzi | 2012 |